Trials / Completed
CompletedNCT02047110
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo for risankizumab | Placebo for risankizumab administered by subcutaneous (SC) injection |
| DRUG | risankizumab | Risankizumab administered by subcutaneous (SC) injection |
Timeline
- Start date
- 2014-01-28
- Primary completion
- 2015-03-05
- Completion
- 2016-07-25
- First posted
- 2014-01-28
- Last updated
- 2019-05-31
- Results posted
- 2019-05-31
Source: ClinicalTrials.gov record NCT02047110. Inclusion in this directory is not an endorsement.